Results 51 to 60 of about 1,869 (168)

Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis

Acta Dermato-Venereologica
Lebrikizumab has previously demonstrated efficacy in Phase 3 trials: ADvocate1 and ADvocate2 (as monotherapy), ADhere, and ADhere-J (in combination with topical corticosteroids).
Akio Tanaka, Ken Igawa, Hidetoshi Takahashi, Ryosuke Shimizu, Yoko Kataoka, Hitoe Torisu-Itakura, Yoji Morisaki, Sonia Montmayeur, Norito Katoh   +8 more
doaj   +1 more source

The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis

Dermatology and Therapy
Introduction Lebrikizumab, a high-affinity IgG4 monoclonal antibody that selectively inhibits interleukin-13 with high binding affinity and slow dissociation rate, prevents the formation of the interleukin-4Rα/interleukin-13Rα1 heterodimer receptor ...
Jennifer Soung, Vivian Laquer, Joseph F. Merola, Angela Moore, Hany Elmaraghy, Chaoran Hu, Maria Lucia Buziqui Piruzeli, Evangeline Pierce, Esther Garcia Gil, Abel D. Jarell   +9 more
doaj   +1 more source

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis

Pharmaceutics, 2023
Atopic dermatitis (AD) is a common chronic inflammatory skin condition that has a significant impact on a patient’s quality of life and requires ongoing management.
Yuliya Lytvyn, Melinda Gooderham
doaj   +1 more source

Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In adults with moderate AD post‐TCS and ‐TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream improved clinical signs and symptoms in the TRuE‐AD4 study. Abstract Background In patients with moderate atopic dermatitis (AD), topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) often do not sufficiently ...
José Manuel Carrascosa, Vimal H. Prajapati, H. Chih‐ho Hong, Viktoria Eleftheriadou, Athanasios Tsianakas, Alexander A. Navarini, Ketty Peris, Eingun James Song, Raj Chovatiya, Sébastien Barbarot, Konstantin Popovic, Haq Nawaz, Qian Li, Vivek Purohit, Andreas Wollenberg   +14 more
wiley   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 11, Page 1831-1839, November 2026.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents

Frontiers in Medicine, 2023
Atopic dermatitis (AD) is a chronic inflammatory disease with a heterogeneous pathogenesis correlated with dysregulation of the immune system and a prevalence of the T2-mediated immune pathway.
Carlo Caffarelli, Arianna Giannetti, Giuliana Giannì, Giampaolo Ricci   +3 more
doaj   +1 more source

Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease

Clinical and Translational Allergy, Volume 16, Issue 10, October 2026.
ABSTRACT Background Aspirin‐exacerbated respiratory disease (AERD), also termed nonsteroidal anti‐inflammatory drug exacerbated respiratory disease (NERD), is characterized by asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity to cyclooxygenase‐1 inhibitors, frequently resulting in severe, treatment‐refractory airway disease ...
Jennifer K. Priessnitz, Anastasia Hagopian, Alison J. Patev, Joseph K. Han, Kent K. Lam   +4 more
wiley   +1 more source

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE) [PDF]

, 2018
Background Interleukin (IL)-13 plays a key role in type 2 inflammation and is an emerging pathogenic mediator in atopic dermatitis. Objective We investigated the efficacy and safety of lebrikizumab, an anti-IL-13 monoclonal antibody, as add-on to topical
Eric L. Simpson, DeBusk, Kendra, Taïeb, Alain, Sofen, Howard, Owen, Ryan, Bieber, Thomas, Simpson, Eric L., Chin-Yu Lin, Ryan Owen, Athina Voulgari, Lin, Chin-Yu, Theodore A. Omachi, Howard Sofen, Voulgari, Athina, Lawrence F. Eichenfield, Omachi, Theodore A., Castro, Marcela, Thomas Bieber, Karl Yen, Yen, Karl, Carsten Flohr, Putnam, Wendy, Wendy Putnam, Alain Taïeb, Kendra DeBusk, Marcela Castro, Flohr, Carsten; id_orcid, Eichenfield, Lawrence F.   +27 more
core   +1 more source

Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate‐to‐Severe Atopic Dermatitis

Allergy, Volume 81, Issue 10, Page 3599-3607, October 2026.
Atopic dermatitis (AD) is characterized by microbial dysbiosis. This study aimed to evaluate the effects of abrocitinib, a JAK1‐selective inhibitor, on the skin microbiome and its potential associations with clinical outcomes in patients with AD. Abrocitinib treatment was associated with increased skin microbial diversity and decreased Staphylococcus ...
Madeline Kim, Ester Del Duca, Joel Correa Da Rosa, Juliana Pulsinelli, Yeriel Estrada, Dan Xu, Gary Chan, Allshine Chen, Erman Güler, Karen Page, Emma Guttman‐Yassky   +10 more
wiley   +1 more source

HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis

JEADV Clinical Practice, Volume 5, Issue 3, Page 974-978, September 2026.
ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD developed a rapidly disseminating eruption ...
Mohammed Shanshal, Emily Moon, Georgios Kallikas   +2 more
wiley   +1 more source